InflaRx N.V.(US:IFRX) ZACKS·2024-08-08 13:50分组1 - InflaRx N.V. reported a quarterly loss of $0.26 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.21, and compared to a loss of $0.15 per share a year ago, indicating an earnings surprise of -23.81% [1] - The company posted revenues of $0.01 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 83%, while revenues were zero a year ago [2] - InflaRx shares have declined approximately 13.5% since the beginning of the year, contrasting with the S&P 500's gain of 9% [3] 分组2 - The earnings outlook for InflaRx is mixed, with the current consensus EPS estimate for the coming quarter at -$0.22 on $0.06 million in revenues, and -$0.81 on $0.37 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 37% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8] 分组3 - Fortrea Holdings Inc., another company in the same industry, is expected to report quarterly earnings of $0.07 per share, reflecting a year-over-year change of -86.5%, with revenues anticipated to be $686.08 million, down 13.5% from the previous year [9][10]